ArticleNature communications2025

Longitudinal omics data and preclinical treatment suggest the proteasome inhibitor carfilzomib as therapy for ibrutinib-resistant CLL.

Lavinia Arseni et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.